We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: cardiovascular outcomes
MedXY News
EnglishTag

cardiovascular outcomes

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Cardiovascular Risks of CAR-T Therapy in Older Adults: Insights from US Medicare Data
Cardiologyolder adultsHematologic Malignancies

Cardiovascular Risks of CAR-T Therapy in Older Adults: Insights from US Medicare Data

By MedXY|Sep 19, 2026

Among older adults receiving CAR-T therapy, 5.8% experienced major adverse cardiovascular events (MACE), associated with increased mortality. Pre-existing cardiac conditions heightened risk, underscoring the need for cardiovascular monitori

Intracoronary Imaging-Guided PCI: Updated Meta-Analysis Validates Cardiovascular Outcome Benefits
CardiologyPercutaneous Coronary InterventionIntracoronary Imaging
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Intracoronary Imaging-Guided PCI: Updated Meta-Analysis Validates Cardiovascular Outcome Benefits

By MedXY|Sep 19, 2026

This updated meta-analysis of 28 RCTs reveals significant reductions in cardiovascular events and mortality with intracoronary imaging-guided PCI versus angiography-guided PCI, highlighting the importance of lesion and geographic factors in

Impact of Digitalis Glycosides on Cardiovascular Outcomes in HFmrEF and HFrEF: A Comprehensive Evidence Synthesis
Cardiologydigitalis glycosidesheart failure with mid-range ejection fraction

Impact of Digitalis Glycosides on Cardiovascular Outcomes in HFmrEF and HFrEF: A Comprehensive Evidence Synthesis

By MedXY|Sep 17, 2026

Digitalis glycosides reduce cardiovascular death or worsening heart failure events in HFmrEF and HFrEF patients over a median of 36–37 months, supported by randomized trials and meta-analyses highlighting their role in select heart failure

Advancing Prognostic Precision in HFpEF: The LIFE-Preserved Risk Prediction Model
CardiologyHFpEFheart failure

Advancing Prognostic Precision in HFpEF: The LIFE-Preserved Risk Prediction Model

By MedXY|Sep 11, 2026

The LIFE-Preserved model accurately predicts short-term and lifetime risks of heart failure hospitalization or cardiovascular death in HFpEF patients, enabling tailored clinical risk stratification and improved management.

Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness: A Comprehensive Review
CardiologyGLP-1 receptor agonistsserious mental illness

Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness: A Comprehensive Review

By MedXY|Sep 2, 2026

GLP-1 receptor agonists reduce mortality and cardiovascular events more effectively than SGLT2 inhibitors in serious mental illness (SMI), with early benefits and consistent effects across bipolar disorder, major depression, and schizophren

Refining Myocardial Infarction Diagnosis: A Novel Causal Endotype-Based Classification Beyond Type 1 and Type 2 MI
Cardiologycausal endotypesmyocardial infarction

Refining Myocardial Infarction Diagnosis: A Novel Causal Endotype-Based Classification Beyond Type 1 and Type 2 MI

By MedXY|Sep 1, 2026

This study introduces a causal endotype-based classification of myocardial infarction, revealing distinct underlying mechanisms and clinical outcomes beyond the traditional type 1/type 2 framework, potentially improving MI diagnosis and man

Evaluating the Clinical and Health Outcomes of Financial Incentives in Hypertension Management: A Comprehensive Review
CardiologyBlood Pressure Controlfinancial incentives

Evaluating the Clinical and Health Outcomes of Financial Incentives in Hypertension Management: A Comprehensive Review

By MedXY|Aug 18, 2026

This review synthesizes evidence on physician-focused financial incentives for hypertension control, highlighting nuanced impacts on clinical decisions, documented blood pressure control, and cardiovascular outcomes, with a focus on both ov

Elevated Endogenous Insulin and Insulin Resistance in Progressive Diastolic Dysfunction and Cardiovascular Risk: A Comprehensive Clinical Review
Cardiologydiastolic dysfunctionheart failure with preserved ejection fraction

Elevated Endogenous Insulin and Insulin Resistance in Progressive Diastolic Dysfunction and Cardiovascular Risk: A Comprehensive Clinical Review

By MedXY|Aug 11, 2026

Elevated endogenous insulin and insulin resistance independently predict progression of diastolic dysfunction and increased cardiovascular mortality, highlighting early metabolic dysregulation as a target to prevent heart failure with prese

Early Rhythm Control Reduces Cardiovascular Events in Atrial Fibrillation Patients With Chronic Kidney Disease
Cardiologyatrial fibrillationchronic kidney disease

Early Rhythm Control Reduces Cardiovascular Events in Atrial Fibrillation Patients With Chronic Kidney Disease

By MedXY|Jul 28, 2026

A predefined subanalysis of EAST-AFNET 4 shows early rhythm control safely reduces cardiovascular events in recently diagnosed AF patients with CKD, with a trend toward greater benefit in this high-risk group.

Impact of Hypothyroidism on Short-Term and Long-Term Outcomes of Coronary Artery Bypass Graft Surgery
Clinical UpdatesCABGcardiovascular outcomes

Impact of Hypothyroidism on Short-Term and Long-Term Outcomes of Coronary Artery Bypass Graft Surgery

By MedXY|Jul 4, 2026

Hypothyroidism increases the incidence of CABG and is linked to higher risks of postoperative complications, heart failure, stroke, and major adverse cardiovascular events, highlighting the importance of preoperative thyroid function optimi

Enhancing Risk Prediction After TAVI: The COPD-Augmented R₂CHA₂DS₂-VA Score and Its Prognostic Value
Cardiologycardiovascular outcomesCOPD

Enhancing Risk Prediction After TAVI: The COPD-Augmented R₂CHA₂DS₂-VA Score and Its Prognostic Value

By MedXY|Jul 3, 2026

A novel risk score incorporating COPD and graded renal dysfunction improves prediction of one-year mortality post-TAVI, showing excellent internal validity but requiring external validation before clinical use.

Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes
Cardiologycardiovascular outcomesGLP-1 receptor agonists

Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes

By MedXY|Jun 10, 2026

A multinational real-world study found broadly similar cardiovascular effectiveness across individual GLP-1 receptor agonists and SGLT2 inhibitors in metformin-treated type 2 diabetes, including among patients with established cardiovascula

Exploring the Impact of Body Mass Index on Heart Failure Outcomes: Insights from Mendelian Randomization
CardiologyBody Mass Indexcardiovascular outcomes

Exploring the Impact of Body Mass Index on Heart Failure Outcomes: Insights from Mendelian Randomization

By MedXY|Jun 10, 2026

This study leverages Mendelian randomization to demonstrate that genetically elevated BMI is associated with increased mortality and adverse cardiovascular outcomes in heart failure, irrespective of ejection fraction status, underscoring po

Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study
CardiologyBody Mass Indexcardiovascular outcomes

Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study

By MedXY|Jun 10, 2026

This study uses Mendelian randomization to show that higher genetically predicted BMI is associated with increased all-cause mortality and cardiovascular events in heart failure patients, regardless of ejection fraction status.

Cardiovascular Benefit of CPAP May Be Greater in High-Risk Obstructive Sleep Apnoea
Cardiologycardiovascular outcomesCPAP

Cardiovascular Benefit of CPAP May Be Greater in High-Risk Obstructive Sleep Apnoea

By MedXY|May 15, 2026

This pooled analysis found that CPAP may lower cardiovascular event risk mainly in patients with high-risk obstructive sleep apnoea, especially those with stronger heart-rate surges or greater oxygen deprivation during sleep.

Rationale and Design of CARDIO-TTRansform: A Phase 3 Trial of Eplontersen for Transthyretin Amyloid Cardiomyopathy
CardiologyCARDIO-TTRansformcardiovascular outcomes

Rationale and Design of CARDIO-TTRansform: A Phase 3 Trial of Eplontersen for Transthyretin Amyloid Cardiomyopathy

By MedXY|May 10, 2026

CARDIO-TTRansform is a global Phase 3 trial evaluating eplontersen’s efficacy and safety in reducing cardiovascular events in transthyretin amyloid cardiomyopathy patients receiving standard care, including TTR stabilizers. With 1,432

No Clear Winner: Real-World Evidence Shows GLP-1RAs and SGLT2 Inhibitors Deliver Comparable Cardiovascular Benefits in Type 2 Diabetes
Cardiologycardiovascular outcomescomparative effectiveness

No Clear Winner: Real-World Evidence Shows GLP-1RAs and SGLT2 Inhibitors Deliver Comparable Cardiovascular Benefits in Type 2 Diabetes

By MedXY|Apr 18, 2026

A large-scale multinational study of over 1.2 million patients reveals that individual GLP-1 receptor agonists and SGLT2 inhibitors offer broadly similar cardiovascular protection in type 2 diabetes, challenging assumptions about meaningful

Integrated Strategies for Stroke Prevention and Management: From Evidence-Based Dietary Patterns to Systemic Adherence
Clinical Updatescardiovascular outcomesMediterranean diet

Integrated Strategies for Stroke Prevention and Management: From Evidence-Based Dietary Patterns to Systemic Adherence

By MedXY|Apr 9, 2026

This review synthesizes recent evidence on the neuroprotective effects of healthy dietary patterns (Mediterranean, MIND), the synergistic impact of lifestyle and pharmacotherapy (GLP-1), and systemic advances in acute stroke care and second

Evolution and Future Frontiers of PCSK9 Inhibition: From Genetic Discovery to Genomic Medicine
Clinical Updatescardiovascular outcomesgene therapy

Evolution and Future Frontiers of PCSK9 Inhibition: From Genetic Discovery to Genomic Medicine

By MedXY|Mar 25, 2026

This review synthesizes the trajectory of PCSK9 inhibitors, from pivotal monoclonal antibody trials to emerging RNA interference and gene-editing technologies, emphasizing their role in achieving ultra-low LDL-C levels and reducing major ad

GLP-1 Receptor Agonists Significantly Reduce MACE Risk Across the CKD Spectrum, Yet Prescription Rates Remain Suboptimal
Diabetes & Endocrinologycardiovascular outcomeschronic kidney disease

GLP-1 Receptor Agonists Significantly Reduce MACE Risk Across the CKD Spectrum, Yet Prescription Rates Remain Suboptimal

By MedXY|Feb 3, 2026

Recent data highlights that GLP-1 receptor agonists (GLP1-RAs) reduce cardiovascular risk in patients with chronic kidney disease (CKD), yet real-world prescription rates remain alarmingly low despite these proven benefits across various st

1 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities